Day: March 15, 2023

Company on Track for PROC Phase 3, Pivotal Trial Readout in Mid 2023; Ends Year with Strengthened Cash Position HOUSTON, March 15, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today reported fourth quarter and full year ended December 31, 2022 financial results and provided corporate updates. “As we reflect on a productive 2022, Aravive remains committed to driving progress across all aspects of our business,” said Gail McIntyre, Ph.D., DABT, Chief Executive Officer of Aravive. “We are on track with development activities around our PROC Phase 3 program, and we anticipate delivering topline results in mid-2023. Our trials in both clear cell renal cell carcinoma and pancreatic cancer continue...

Data from Phase 2 study of HB-200 in combination with pembrolizumab in head and neck cancers expected in 2Q 2023Phase 1 HB-300 trial in metastatic castration-resistant prostate cancer open for enrollmentKRAS program (HB-700) achieved its first milestone payment in the Roche collaboration in February 2023; plan to submit IND in 1H 2024Strengthened cash position of $113.4 million at year-end; additional $15.0 million cash inflow from collaboration milestones in early 2023NEW YORK and VIENNA, March 15, 2023 (GLOBE NEWSWIRE) — HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today reported financial results and provided a corporate update for the fourth quarter and full year 2022, as well as the outlook for 2023. “We made...

Full Year 2022 revenue growth of 30% exceeds annual 2022 outlookFourth quarter ROW Betting segment revenue grew 29% with Adjusted EBITDA margin of 44%Fourth quarter U.S. segment revenue grew 77%; positive Adjusted EBITDA for second consecutive quarter2023 annual outlook with growth of 24% to 26% for revenue and 25% to 33% for Adjusted EBITDA ST. GALLEN, Switzerland, March 15, 2023 (GLOBE NEWSWIRE) — Sportradar Group AG (NASDAQ: SRAD) (“Sportradar” or the “Company”), a leading global technology company focused on enabling next generation engagement in sports through providing business-to-business solutions to the global sports betting industry, today announced financial results for its fourth quarter and full year ended December 31, 2022. Full Year 2022 Highlights and Annual OutlookRevenue for the full year of 2022 increased 30%...

Total Revenues for Fiscal Year 2022 of $129.3 Million Represented Growth of 25% Compared to Fiscal Year 2021; Fourth Quarter 2022 Revenues of $45.4 Million Represented a 44% Increase Year–over–Year Fiscal Year 2022 EBITDA of $17.8 million, Represented Margins of 14%, and a 3x Increase Over Fiscal Year 2021 Recorded Highest Annual Operating Cash Flow in Kamada’s History of $28.6 Million in Fiscal Year 2022; $34.3 Million Cash Position as of December 31, 2022, Nearly Double Cash Position at Year-End 2021  Fiscal Year 2023 Revenues Expected to be in Range of $138 Million to $146 Million; 2023 EBITDA Anticipated to be in Range of $22 Million to $26 Million; Mid-Point Expected EBITDA Represents Approximately 35% Growth Year–over–Year Strong 2022 Results and 2023 Positive Outlook Driven by Multiple Growth Drivers,...

– 10 ongoing or planned clinical trials throughout 2023 to advance both differentiated clinical programs, anti-TIGIT monoclonal antibody EOS-448/GSK4428859A and adenosine A2A receptor antagonist inupadenant – EOS-984, a first-in-class program targeting a new mechanism of action in the adenosine pathway, expected to enter clinical studies in mid-2023 – Cash and investment balance of $731.4MM as of December 31, 2022, expected to provide runway into 2026 WATERTOWN, Mass. and GOSSELIES, Belgium, March 15, 2023 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today reported financial results for the fourth quarter and full year ended December 31, 2022. “Building...

Fiscal Year 2023 Outlook Calls for Accelerated Growth and Improved Margins Company Receives Financing Commitments of $425 Million MALMÖ, Sweden, March 15, 2023 (GLOBE NEWSWIRE) — Oatly Group AB (Nasdaq: OTLY) (“Oatly” or the “Company”), the world’s original and largest oat drink company, today announced financial results for the fourth quarter and twelve months ended December 31, 2022. Toni Petersson, Oatly’s CEO, commented, “I am proud of what the Oatly team accomplished in 2022. We took bold actions to strengthen our management team, transition our supply chain to a more asset-light model, and simplify our cost structure. We finished the year with a solid fourth quarter, and we have continued that momentum into 2023 by closing the Ya YA Foods transaction and raising $425 million in financing commitments.” Petersson continued,...

BEIJING, March 15, 2023 (GLOBE NEWSWIRE) — Chindata Group Holdings Limited (“Chindata Group” or the “Company”) (Nasdaq: CD), a leading carrier-neutral hyperscale data center solution provider in Asia-Pacific emerging markets, today announced its unaudited financial results for the fourth quarter and the fiscal year of 2022 ended December 31, 2022. To supplement the Company’s consolidated financial results presented in accordance with U.S. GAAP, Chindata Group uses adjusted EBITDA, adjusted EBITDA margin, adjusted net income and adjusted net income margin as non-GAAP financial measures, which are described further below. Recent Financial and Operating HighlightsRealizing ten straight quarters of consensus beat and 2022 full year guidance upbeat, 2023 full year guidance implies 30% growth in revenue. Revenue and adjusted EBITDA...